Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

INTRODUCTION: Effective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2013
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3898123/
https://ncbi.nlm.nih.gov/pubmed/24158787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-013-0060-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki